PSA SCREENING REVIEW ARTICLE PDF



Psa Screening Review Article Pdf

Prostate cancer screening Cleveland Clinic Journal of. Review and Reassessment in the PSA Screening Era (Article begins on next page) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Wei, Melissa Y., and Edward L. Giovannucci. 2012. Lycopene, tomato products, and prostate cancer incidence: A review and, 01/05/2014В В· The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings.

PSA screening Back to the future Cleveland Clinic

[PDF] Prostate cancer screening and early detection. No benefit was found for PSA-based screening in men aged 70 years and older. On the basis of its review, the USPSTF concluded that the decision for men aged 55 to 69 years to have PSA-based screening should be an individual one and should include a discussion of the potential benefits and harms. Here, 2 experts—an internist and a urologist, This article reviews the three largest randomized trials of PSA-based prostate cancer screening and the benefits and disadvantages of general PSA screening. It gives an overview about the strategies to avoid the harms from overdetection and overtreatment without missing clinically relevant tumors..

31/01/2013В В· Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review. One approach is to try to improve on the test that measures the total PSA level, as described in Screening Tests for Prostate Cancer3. Another approach is to develop new tests based on other forms of PSA, or other tumor markers. Several newer tests seem to be more accurate than the PSA test, including:

After the systematic literature review, 28 articles were identified as providing evidence of mortality reduction from prostate cancer, including 5 observational studies for DRE screening, 1 meta-analysis, 3 randomized controlled trials and 19 observational studies for PSA screening. Although several studies showed that PSA screening had a pdf. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era . 2012. Melissa Wei. Download with Google Download with Facebook or download with email. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era. Download. Lycopene, tomato products, and prostate cancer incidence: A review and

As a result, Dr. Smith tested each of his male patients—including the elderly—annually for prostate cancer with PSA and digital rectal exam. More of his patients underwent biopsy and subsequent surgery as a result of their PSA screening, and a higher incidence of prostate cancer was diagnosed among them. Two patients had died as a result of Family History and PSA Testing Running Head: Family History and PSA Testing A Review of PSA Screening Prevalence and Risk Perceptions for First-Degree Relatives of Men with Prostate Cancer McDowell, M. E., Occhipinti, S., Gardiner, RA., Baade, P., Steginga, S. K

Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era Article (PDF Available) in Journal of Oncology 2012:271063 В· May 2012 with 111 Reads pdf. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era . 2012. Melissa Wei. Download with Google Download with Facebook or download with email. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era. Download. Lycopene, tomato products, and prostate cancer incidence: A review and

01/04/2013В В· Context. Prostate cancer screening is controversial. This study presents an evidence review commissioned by the US Preventive Services Task Force (USPSTF) in developing their updated recommendations regarding prostate-specific antigen (PSA) screening. 01/05/2014В В· The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings

Prostate-Specific Antigen–Based Screening for Prostate

psa screening review article pdf

Prostate Cancer Screening. Lycopene has been proposed to protect against prostate cancer through various properties including decreased lipid oxidation, inhibition of cancer cell proliferation, and most notably potent antioxidant properties. Epidemiologic studies on the association between lycopene and prostate cancer incidence have yielded mixed results. Detection of an, RESEARCH ARTICLE Open Access Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models Sabina Sanghera1*, Joanna Coast1,2, Richard M. Martin3,4, Jenny L. Donovan2,3 and Syed Mohiuddin1,2.

PSA Screening for Prostate Cancer in Men under the Age of. However, evidence supporting an overall survival advantage in men undergoing PSA screening is controversial, leading to a lack of consensus on guidelines. The present review article provides an overview of the most important studies on PSA screening including the latest updates of large trials. In addition, modern concepts in early detection of, The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality.

Screening by Prostate-Specific Antigen and Digital Rectal

psa screening review article pdf

About Prostate Cancer. BACKGROUND Despite more than a decade of prostate-specific antigen (PSA)-based screening, the proven impact of screening on mortality due to prostate cancer continues to be controversial. METHODS A literature review of issues pertaining to the epidemiology, screening, early detection, and mortality as they relate to prostate cancer was conducted. The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality.

psa screening review article pdf


The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality 01/10/2002В В· In this article we review the natural history and management of prostate cancer. However, although screening measures lead to a higher rate of detection, for small bulk localised prostate cancer it remains unclear whether early detection and early treatment will lead to an overall decrease in mortality.

04/03/2014В В· Introduction: The State of the Evidence. Ethan Basch. Despite multiple prospective clinical trials, observational studies, retrospective analyses, and simulation models, intense controversy persists regarding the value of screening for prostate cancer with the prostate-specific antigen (PSA) test. Widespread testing without evidence of efficacy. The PSA test was approved by the US Food and Drug Administration (FDA) in 1986. 5 Its potential to detect early prostate cancer in the hope of decreasing morbidity and mortality led to widespread PSA screening in the 1990s, before data on the efficacy of routine screening existed.

Family History and PSA Testing Running Head: Family History and PSA Testing A Review of PSA Screening Prevalence and Risk Perceptions for First-Degree Relatives of Men with Prostate Cancer McDowell, M. E., Occhipinti, S., Gardiner, RA., Baade, P., Steginga, S. K the United Kingdom to PSA screening versus usual management.10 In light of this new evidence, we conducted an update of prior systematic reviews by our group to address the potential benefits and harms of PSA based screening.4 5 This systematic review informed the parallel guideline published in a …

For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a the United Kingdom to PSA screening versus usual management.10 In light of this new evidence, we conducted an update of prior systematic reviews by our group to address the potential benefits and harms of PSA based screening.4 5 This systematic review informed the parallel guideline published in a …

18/09/2018В В· The USPSTF commissioned a systematic review on PSA screening. {The review searched MEDLINE, EMBASE/Excerpta Medica, Web of Science, and Cochrane Central Register of Controlled Trials (Jul 2011 to Jul 2017), and reference lists, and used article alerts and journal hand searches (Feb 2018). PDF Background Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk

Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era Article (PDF Available) in Journal of Oncology 2012:271063 · May 2012 with 111 Reads No benefit was found for PSA-based screening in men aged 70 years and older. On the basis of its review, the USPSTF concluded that the decision for men aged 55 to 69 years to have PSA-based screening should be an individual one and should include a discussion of the potential benefits and harms. Here, 2 experts—an internist and a urologist

04/03/2014В В· Introduction: The State of the Evidence. Ethan Basch. Despite multiple prospective clinical trials, observational studies, retrospective analyses, and simulation models, intense controversy persists regarding the value of screening for prostate cancer with the prostate-specific antigen (PSA) test. 01/05/2014В В· The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings

Prostate-Specific Antigen (PSA) Screening for Prostate

psa screening review article pdf

Prostate Cancer Screening. Widespread testing without evidence of efficacy. The PSA test was approved by the US Food and Drug Administration (FDA) in 1986. 5 Its potential to detect early prostate cancer in the hope of decreasing morbidity and mortality led to widespread PSA screening in the 1990s, before data on the efficacy of routine screening existed., 3. Screening and early detection Screening for PCa remains one of the most controversial topics in the urologic literature. A Cochrane review [13] suggests that PSA screening is associated with an increased diagnosis rate (relative risk [RR]: 1.3; 95% confidence interval [CI], 1.02–1.65), the ….

Prostate cancer measuring PSA Pezaro - 2014 - Internal

Prostate Cancer Early Detection Diagnosis and Staging. screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower the death rate from prostate cancer. However, questions have been raised about this study, because some men in the non-screening group actually were screened during the study, which might have affected the results.€, Background: The potential role of prostate cancer screening in reducing mortality is uncertain. To examine whether screening with the prostate-specific antigen (PSA) test or digital rectal examination is associated with reduced prostate cancer mortality, we conducted a population-based case.

To the Editor: In their article on men’s health, 1 Chaitoff and colleagues present the scenario of a 60-year-old patient, with no other history given, whose recent screening prostate-specific antigen (PSA) level was 5.1 ng/mL, and who asks his doctor: This article reviews the three largest randomized trials of PSA-based prostate cancer screening and the benefits and disadvantages of general PSA screening. It gives an overview about the strategies to avoid the harms from overdetection and overtreatment without missing clinically relevant tumors.

RESEARCH ARTICLE Open Access Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models Sabina Sanghera1*, Joanna Coast1,2, Richard M. Martin3,4, Jenny L. Donovan2,3 and Syed Mohiuddin1,2 Prostate cancer is the most common noncutaneous malignancy in US men, and is most frequently diagnosed through prostate-specific antigen (PSA)-based screening. Nevertheless, PSA testing has become increasingly controversial. In this review, we will present the evidence supporting the role of PSA in prostate cancer screening.

04/11/2014 · Evidence suggests that a patient’s perceived vulnerability to the disease, as a result of family history or otherwise, and physician recommendation are both associated with patient request for screening with the PSA test.50 Although high-quality evidence on the best way to facilitate informed decision-making about prostate cancer screening is BACKGROUND Despite more than a decade of prostate-specific antigen (PSA)-based screening, the proven impact of screening on mortality due to prostate cancer continues to be controversial. METHODS A literature review of issues pertaining to the epidemiology, screening, early detection, and mortality as they relate to prostate cancer was conducted.

recommendations based on a linked systematic review. 1 The review was triggered by a large scale, cluster ran-domised trial on PSA screening in men without a previous diagnosis of prostate cancer published in 2018 (box 1). 2 It found no difference between one-time PSA screening and standard practice in prostate cancer mortality but found However, evidence supporting an overall survival advantage in men undergoing PSA screening is controversial, leading to a lack of consensus on guidelines. The present review article provides an overview of the most important studies on PSA screening including the latest updates of large trials. In addition, modern concepts in early detection of

01/05/2014 · The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings the United Kingdom to PSA screening versus usual management.10 In light of this new evidence, we conducted an update of prior systematic reviews by our group to address the potential benefits and harms of PSA based screening.4 5 This systematic review informed the parallel guideline published in a …

01/05/2014В В· The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings The value of prostate-specific antigen (PSA) for screening and management of prostate cancer (CaP) continues to engender much controversy in the medical and lay literature. This review is intended to critically analyze the literature to assess the utility of adding the calculation of PSA velocity (PSAV) in the screening and management of CaP.

Review Article Multiparametric MRI in the PSA Screening Era ArvinK.George,PeterA.Pinto,andSoroushRais-Bahrami National Cancer Institute, Urologic Oncology Branch, National Institutes of Health,Center Drive,-W, Building, After the systematic literature review, 28 articles were identified as providing evidence of mortality reduction from prostate cancer, including 5 observational studies for DRE screening, 1 meta-analysis, 3 randomized controlled trials and 19 observational studies for PSA screening. Although several studies showed that PSA screening had a

PDF Background Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower the death rate from prostate cancer. However, questions have been raised about this study, because some men in the non-screening group actually were screened during the study, which might have affected the results.€

Prostate cancer is the most common noncutaneous malignancy in US men, and is most frequently diagnosed through prostate-specific antigen (PSA)-based screening. Nevertheless, PSA testing has become increasingly controversial. In this review, we will present the evidence supporting the role of PSA in prostate cancer screening. Widespread testing without evidence of efficacy. The PSA test was approved by the US Food and Drug Administration (FDA) in 1986. 5 Its potential to detect early prostate cancer in the hope of decreasing morbidity and mortality led to widespread PSA screening in the 1990s, before data on the efficacy of routine screening existed.

BACKGROUND Despite more than a decade of prostate-specific antigen (PSA)-based screening, the proven impact of screening on mortality due to prostate cancer continues to be controversial. METHODS A literature review of issues pertaining to the epidemiology, screening, early detection, and mortality as they relate to prostate cancer was conducted. screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower the death rate from prostate cancer. However, questions have been raised about this study, because some men in the non-screening group actually were screened during the study, which might have affected the results.€

08/05/2018 · For KQ2, RCTs and cohort studies of asymptomatic men undergoing PSA screening or prostate biopsy after abnormal screening results were included that assessed the frequency of false-positive PSA screening, physical or psychological harms … Prostate Cancer Screening ELIE MULHEM, MD, A Cochrane review of five RCTs concluded that PSA screening does not decrease pros-tate cancer–specific or overall mortality. Screening increased

04/03/2014В В· Introduction: The State of the Evidence. Ethan Basch. Despite multiple prospective clinical trials, observational studies, retrospective analyses, and simulation models, intense controversy persists regarding the value of screening for prostate cancer with the prostate-specific antigen (PSA) test. 01/10/2002В В· In this article we review the natural history and management of prostate cancer. However, although screening measures lead to a higher rate of detection, for small bulk localised prostate cancer it remains unclear whether early detection and early treatment will lead to an overall decrease in mortality.

PSA testing When it’s useful when it’s not

psa screening review article pdf

PSA testing When it’s useful when it’s not. 01/12/2017 · Forty years after its discovery, a reanalysis of the two largest trials to date, controversially suggests that prostate-specific antigen (PSA) screening may actually be beneficial. Most healthcare organisations do not recommend PSA screening for prostate cancer,1 2 mainly in response to conflicting evidence about the benefits and clear evidence, Controversy stems from conflicting research studies regarding the efficacy of PSA screening with regard to improved survival rates. This article serves as a critical review of the current guidelines and research to determine which screening practices may be most beneficial to utilize with patients..

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1

psa screening review article pdf

About Prostate Cancer. 31/01/2013В В· Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review. 01/12/2017В В· Forty years after its discovery, a reanalysis of the two largest trials to date, controversially suggests that prostate-specific antigen (PSA) screening may actually be beneficial. Most healthcare organisations do not recommend PSA screening for prostate cancer,1 2 mainly in response to conflicting evidence about the benefits and clear evidence.

psa screening review article pdf


Widespread testing without evidence of efficacy. The PSA test was approved by the US Food and Drug Administration (FDA) in 1986. 5 Its potential to detect early prostate cancer in the hope of decreasing morbidity and mortality led to widespread PSA screening in the 1990s, before data on the efficacy of routine screening existed. 01/12/2017В В· Forty years after its discovery, a reanalysis of the two largest trials to date, controversially suggests that prostate-specific antigen (PSA) screening may actually be beneficial. Most healthcare organisations do not recommend PSA screening for prostate cancer,1 2 mainly in response to conflicting evidence about the benefits and clear evidence

Screening of prostate cancer with prostate-specific antigen (PSA) is a highly controversial issue. One part of the controversy is due to the confusion between population screening and early diagnosis, another derives from problems related to the quality of existing screening studies, the results of 01/01/2019В В· It is remarkable that even though 30 years have passed since the introduction of prostate-specific antigen (PSA)2 into US clinical practice, researchers and clinicians are still debating its value for prostate cancer screening. The US Preventive Services Task Force has seesawed from stating that PSA testing was a personal decision for the

31/01/2013В В· Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review. After the systematic literature review, 28 articles were identified as providing evidence of mortality reduction from prostate cancer, including 5 observational studies for DRE screening, 1 meta-analysis, 3 randomized controlled trials and 19 observational studies for PSA screening. Although several studies showed that PSA screening had a

18/09/2018 · The USPSTF commissioned a systematic review on PSA screening. {The review searched MEDLINE, EMBASE/Excerpta Medica, Web of Science, and Cochrane Central Register of Controlled Trials (Jul 2011 to Jul 2017), and reference lists, and used article alerts and journal hand searches (Feb 2018). No benefit was found for PSA-based screening in men aged 70 years and older. On the basis of its review, the USPSTF concluded that the decision for men aged 55 to 69 years to have PSA-based screening should be an individual one and should include a discussion of the potential benefits and harms. Here, 2 experts—an internist and a urologist

Prostate cancer is the most common noncutaneous malignancy in US men, and is most frequently diagnosed through prostate-specific antigen (PSA)-based screening. Nevertheless, PSA testing has become increasingly controversial. In this review, we will present the evidence supporting the role of PSA in prostate cancer screening. 01/01/2019В В· It is remarkable that even though 30 years have passed since the introduction of prostate-specific antigen (PSA)2 into US clinical practice, researchers and clinicians are still debating its value for prostate cancer screening. The US Preventive Services Task Force has seesawed from stating that PSA testing was a personal decision for the

However, evidence supporting an overall survival advantage in men undergoing PSA screening is controversial, leading to a lack of consensus on guidelines. The present review article provides an overview of the most important studies on PSA screening including the latest updates of large trials. In addition, modern concepts in early detection of After the systematic literature review, 28 articles were identified as providing evidence of mortality reduction from prostate cancer, including 5 observational studies for DRE screening, 1 meta-analysis, 3 randomized controlled trials and 19 observational studies for PSA screening. Although several studies showed that PSA screening had a

Without high-quality studies to assess the benefits of screening, in 2008 the US Preventive Services Task Force (USPSTF) concluded that there was insufficient evidence to make a recommendation on PSA-based screening for prostate cancer in men younger than 75 years (I statement) but recommended against use of the PSA test for men 75 years and As a result, Dr. Smith tested each of his male patients—including the elderly—annually for prostate cancer with PSA and digital rectal exam. More of his patients underwent biopsy and subsequent surgery as a result of their PSA screening, and a higher incidence of prostate cancer was diagnosed among them. Two patients had died as a result of

BACKGROUND Despite more than a decade of prostate-specific antigen (PSA)-based screening, the proven impact of screening on mortality due to prostate cancer continues to be controversial. METHODS A literature review of issues pertaining to the epidemiology, screening, early detection, and mortality as they relate to prostate cancer was conducted. As a result, Dr. Smith tested each of his male patients—including the elderly—annually for prostate cancer with PSA and digital rectal exam. More of his patients underwent biopsy and subsequent surgery as a result of their PSA screening, and a higher incidence of prostate cancer was diagnosed among them. Two patients had died as a result of

Family History and PSA Testing Running Head: Family History and PSA Testing A Review of PSA Screening Prevalence and Risk Perceptions for First-Degree Relatives of Men with Prostate Cancer McDowell, M. E., Occhipinti, S., Gardiner, RA., Baade, P., Steginga, S. K 01/04/2013В В· Context. Prostate cancer screening is controversial. This study presents an evidence review commissioned by the US Preventive Services Task Force (USPSTF) in developing their updated recommendations regarding prostate-specific antigen (PSA) screening.

Purpose: To review current practice in the use of Prostate Specific Antigen (PSA) testing and assess the overall risks and benefits of PSA testing for Adenocarcinoma of the Prostate, specifically in men under age 65, and those living with risk factors for the disease. Materials and Methods: An extensive literature review of PSA testing in 31/01/2013В В· Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review.

pdf. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era . 2012. Melissa Wei. Download with Google Download with Facebook or download with email. Lycopene, tomato products, and prostate cancer incidence: A review and reassessment in the psa screening era. Download. Lycopene, tomato products, and prostate cancer incidence: A review and Background: The potential role of prostate cancer screening in reducing mortality is uncertain. To examine whether screening with the prostate-specific antigen (PSA) test or digital rectal examination is associated with reduced prostate cancer mortality, we conducted a population-based case

recommendations based on a linked systematic review. 1 The review was triggered by a large scale, cluster ran-domised trial on PSA screening in men without a previous diagnosis of prostate cancer published in 2018 (box 1). 2 It found no difference between one-time PSA screening and standard practice in prostate cancer mortality but found 08/05/2018 · For KQ2, RCTs and cohort studies of asymptomatic men undergoing PSA screening or prostate biopsy after abnormal screening results were included that assessed the frequency of false-positive PSA screening, physical or psychological harms …

RESEARCH ARTICLE Open Access Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models Sabina Sanghera1*, Joanna Coast1,2, Richard M. Martin3,4, Jenny L. Donovan2,3 and Syed Mohiuddin1,2 RESEARCH ARTICLE Open Access Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models Sabina Sanghera1*, Joanna Coast1,2, Richard M. Martin3,4, Jenny L. Donovan2,3 and Syed Mohiuddin1,2

Les bougies s'allumГЁrent toutes seules ; le soufflet, sans qu'aucun ГЄtre visible lui imprimГўt le mouvement, se prit Г  souffler le feu, en rГўlant comme un vieillard asthmatique, pendant que les pincettes fourgonnaient dans les tisons et que la pelle relevait les cendres. Les figures de style exercices corrigés pdf Tyre Elles relГЁvent de l'art de parler. On trouve les figures de style aussi bien dans la langue de tous les jours, que dans la presse, la publicitГ© et les textes littГ©raires. On distingue plusieurs figures de style, regroupГ©es comme suit : Les figures d'analogie : elles Г©tablissent des relations entre des Г©lГ©ments.